Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Johannsen

Showing results (11-20 of 66) with videos related to

Pageof 7
Sort By:
Aging & Mental Health|January 29, 2011
Development of a dementia assessment quality databasePeter Johannsen, Kasper Jørgensen, Alex Kørner, et al.
Journal of Neuropathology and Experimental Neurology|October 6, 2007
A reassessment of the neuropathology of frontotemporal dementia linked to chromosome 3Ida Elisabeth Holm, Elisabet Englund, Ian R A Mackenzie, et al.
BMJ Open|March 17, 2012
Presymptomatic cerebral blood flow changes in CHMP2B mutation carriers of familial frontotemporal dementia (FTD-3), measured with MRILine Lunau, Kim Mouridsen, Anders Rodell, et al.
Journal of Alzheimer'S Disease Reports|March 4, 2025
Therapeutic drug monitoring for dose optimization in Alzheimer's disease and in dementia with Lewy bodies: A randomized single-blinded clinical trialMichael Hén Forbord Fischer, Ivan Chrilles Zibrandtsen, Peter Johannsen, et al.
Alzheimer Disease and Associated Disorders|May 10, 2016
Early-Onset Dementia: Frequency, Diagnostic Procedures, and Quality Indicators in Three European Tertiary Referral CentersElles Konijnenberg, Seyed-Mohammad Fereshtehnejad, Mara Ten Kate, et al.
Neuroimage|January 20, 2009
Cortical volumes and atrophy rates in FTD-3 CHMP2B mutation carriers and related non-carriersSimon F Eskildsen, Lasse R Østergaard, Anders B Rodell, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|November 13, 2012
Cognitive impairment in the preclinical stage of dementia in FTD-3 CHMP2B mutation carriers: a longitudinal prospective studyJette Stokholm, Thomas W Teasdale, Peter Johannsen, et al.
Alzheimer'S Research & Therapy|January 9, 2025
evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer's diseaseJeffrey L Cummings, Alireza Atri, Howard H Feldman, et al.
Neurology|February 20, 2025
Baseline Characteristics from Evoke and Evoke+: Two Phase 3 Randomized Placebo-controlled Trials of Oral Semaglutide in Patients with Early Alzheimer's Disease (P11-9.013)Philip Scheltens, Alireza Atri, Howard Feldman, et al.
Danish Medical Journal|December 4, 2019
Analgesics use and withdrawal in people with dementia - a register-based Danish study and a systematic reviewAnne Mette Skov Sørensen, Simon Tarp, Peter Johannsen, et al.
Pageof 7

Showing results (11-20 of 66) with videos related to

Sort By:
Pageof 7
Aging & Mental Health|January 29, 2011
Development of a dementia assessment quality databasePeter Johannsen, Kasper Jørgensen, Alex Kørner, et al.
Journal of Neuropathology and Experimental Neurology|October 6, 2007
A reassessment of the neuropathology of frontotemporal dementia linked to chromosome 3Ida Elisabeth Holm, Elisabet Englund, Ian R A Mackenzie, et al.
BMJ Open|March 17, 2012
Presymptomatic cerebral blood flow changes in CHMP2B mutation carriers of familial frontotemporal dementia (FTD-3), measured with MRILine Lunau, Kim Mouridsen, Anders Rodell, et al.
Journal of Alzheimer'S Disease Reports|March 4, 2025
Therapeutic drug monitoring for dose optimization in Alzheimer's disease and in dementia with Lewy bodies: A randomized single-blinded clinical trialMichael Hén Forbord Fischer, Ivan Chrilles Zibrandtsen, Peter Johannsen, et al.
Alzheimer Disease and Associated Disorders|May 10, 2016
Early-Onset Dementia: Frequency, Diagnostic Procedures, and Quality Indicators in Three European Tertiary Referral CentersElles Konijnenberg, Seyed-Mohammad Fereshtehnejad, Mara Ten Kate, et al.
Neuroimage|January 20, 2009
Cortical volumes and atrophy rates in FTD-3 CHMP2B mutation carriers and related non-carriersSimon F Eskildsen, Lasse R Østergaard, Anders B Rodell, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|November 13, 2012
Cognitive impairment in the preclinical stage of dementia in FTD-3 CHMP2B mutation carriers: a longitudinal prospective studyJette Stokholm, Thomas W Teasdale, Peter Johannsen, et al.
Alzheimer'S Research & Therapy|January 9, 2025
evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer's diseaseJeffrey L Cummings, Alireza Atri, Howard H Feldman, et al.
Neurology|February 20, 2025
Baseline Characteristics from Evoke and Evoke+: Two Phase 3 Randomized Placebo-controlled Trials of Oral Semaglutide in Patients with Early Alzheimer's Disease (P11-9.013)Philip Scheltens, Alireza Atri, Howard Feldman, et al.
Danish Medical Journal|December 4, 2019
Analgesics use and withdrawal in people with dementia - a register-based Danish study and a systematic reviewAnne Mette Skov Sørensen, Simon Tarp, Peter Johannsen, et al.
Pageof 7